About this trial
Parents or legal guardian of neonates who signed agreement will receive SMA screening test if their neonates are affected with SMA. The dried blood spots of routine newborn screening samples will be used to test if neonates have lost 2 copies of SMN1 gene. If neonates have positive SMA screening test, further confirmation with multiplex ligation-dependent probe amplification (MLPA) test and prospective motor function monitoring including physical and neurological examinations will be proved to make SMA confirmation. For any confirmed SMA patient, genetic counseling and standard of care will be proved.
Eligibility criteria
Qualifiers
Neonates born in Taiwan who receive regular newborn screening suggested by Ministry of Heath and Welfare.
Parents or legal guardian agree to perform SMA newborn screening.
Disqualifiers
None
Trial design
Treatments tested in this trial
- SMA Newborn Screening
Treatment groups
Sponsors and collaborators
Kaohsiung Medical University Chung-Ho Memorial Hospital
Lead sponsor
The Chinese Foundation of Health
Collaborator
Taipei Institute of Pathology
Collaborator